ARS Pharmaceuticals’ neffy 1mg now available across U.S.

ARS Pharmaceuticals (SPRY) announced neffy 1 mg is now available to patients and caregivers by prescription across the U.S. In March 2025, the U.S. Food and Drug Administration approved neffy for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged four years and older and weigh 15 to less than 30 kilograms. “Many children fear needles, which can lead parents to delay administering needle-based epinephrine treatments. This delay may result in serious consequences,” Eric Karas, Chief Commercial Officer of ARS Pharma, states. “The availability of the 1 mg dose before summer travel, camps, and back-to-school season will help communities better prepare for allergic emergencies. The needle-free design of neffy also eliminates the risk of adverse events, such as accidental injections into the hands or fingers of a child or caregiver, which happens about 3,500 times each year. Now is a great time for parents to reach out to their healthcare providers to ask for neffy as a treatment for their young children.”